Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - November 4, 2013 Category: Cancer & Oncology Source Type: news
EZH2 protein may aid prognostication in resected NSCLC
A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 31, 2013 Category: Cancer & Oncology Source Type: news
FDG-PET parameter predicts locally advanced lung cancer survival
High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 31, 2013 Category: Cancer & Oncology Source Type: news
DNA methylation signature marks recurrence in early stage lung cancer
An international research team has identified a DNA methylation signature that identifies patients with stage I non-small-cell lung cancer who are at high risk for relapse. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 31, 2013 Category: Cancer & Oncology Source Type: news
Complement protein holds diagnostic, prognostic promise in lung cancer
A complement activation product known as “C4d” may have value as a diagnostic and prognostic biomarker for lung cancer, research suggests. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 28, 2013 Category: Cancer & Oncology Source Type: news
Current drugs may harbor small-cell lung cancer promise
Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 28, 2013 Category: Cancer & Oncology Source Type: news
Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC
C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 13, 2013 Category: Cancer & Oncology Source Type: news
HIV infection heralds worse outcomes in NSCLC
Infection with HIV is an indicator of poor prognosis in patients with non-small-cell lung cancer, analysis of epidemiologic data indicates. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 9, 2013 Category: Cancer & Oncology Source Type: news
Use of SHOX2 DNA measurement improves cancer staging tools
Findings indicate that assessment of SHOX2 DNA methylation level in lymph node tissue improves the negative predictive value of endobronchial ultrasound with transbronchial needle aspiration, as well as endoscopic lung cancer staging in general. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - October 4, 2013 Category: Cancer & Oncology Source Type: news
Intercalated erlotinib/chemotherapy shows mixed results in NSCLC
A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 30, 2013 Category: Cancer & Oncology Source Type: news
Time to first cigarette independently predicts lung cancer
The time to first cigarette after waking is an independent risk factor for lung cancer, a Japanese case-control study has found. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 29, 2013 Category: Cancer & Oncology Source Type: news
Immunologic checkpoint inhibitor shows promise in malignant mesothelioma
Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant mesothelioma, results of a single-arm phase II study show. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 27, 2013 Category: Cancer & Oncology Source Type: news
Icotinib matches gefitinib in NSCLC second or third line
Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 26, 2013 Category: Cancer & Oncology Source Type: news
GGO-dominant lung tumors have excellent prognosis
Ground glass opacity-dominant clinical stage IA lung adenocarcinoma is a low-grade malignancy with an “excellent” prognosis, Japanese researchers believe. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 11, 2013 Category: Cancer & Oncology Source Type: news
Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC
Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - September 9, 2013 Category: Cancer & Oncology Source Type: news
